Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29065641 | 0.85 | CYP19A1 (0.72) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL6918238 | 0.82 | CYP19A1 (0.56) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL1165170 | 0.81 | HDAC1 (0.61) | CYP19A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL1165168 | 0.81 | HDAC1 (0.61) | CYP19A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL935182 | 0.81 | CYP19A1 (1.00) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL12022166 | 0.80 | CYP19A1 (0.84) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL1164879 | 0.80 | CD74 (0.56) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL1164877 | 0.80 | CD74 (0.56) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL29275463 | 0.80 | CYP19A1 (0.72) | CYP19A1NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL1164944 | 0.80 | CYP19A1 (0.72) | CYP19A1NPC1RAB9AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102548975-A | Histone deacetylase inhibitors | PORTSMOUTH TECHNOLOGIES LLC | 2012-07-04 | — | — | CN | disclosed |
| EP-2451790-A1 | HISTONE DEACETYLASE INHIBITORS | Anthem Biosciences Private Limited (IN) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | ANTHEM BIOSCIENCES PRIVATE LIMITED (IN) | 2012-04-26 | — | — | US | disclosed |
| WO-2011021209-A1 | HISTONE DEACETYLASE INHIBITORS | PORTSMOUTH TECHNOLOGIES LLC (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011021209-A1 | HISTONE DEACETYLASE INHIBITORS | PORTSMOUTH TECHNOLOGIES LLC (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101099-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC11 | CYP19A1 3106/4885NPC1 1158/4885RAB9A 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.